Beijing Chunlizhengda Medical Instruments

Chunlizhengda Medical Instruments (1858.HK) - Conservative About the Outlook

Equity Bottom-Up
157 Views, 12 Jan 2022 09:02
EXECUTIVE SUMMARY
  • Last year end, Beijing Chunlizhengda Medical Instruments (1858 HK) was listed on the SSE STAR Market, but fell on debut. 
  • The major concerns include performance slowdown, loss of bidding in centralized procurement, problematic sales model, poor gross profit margin, single products risk and weak innovation capability and international business.
  • Our view is that there is no immediate prospect of significant improvement. With too many uncertainties and concerns, we are conservative about Chunlizhengda's outlook despite the large A/H premium.
detail (4-minute read)
WHAT’S TRENDING
logo
Logo
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)

Over 13 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in ... 

x